Report on the TUE Full-Scale Survey (fifth-round survey)

As of June 30, 2023

1. Summary

1.1 Purpose

In order to monitor the long-term health of children, we are continuing the Full-Scale Survey (fifth-round survey), following the Preliminary Baseline Survey for background assessment of thyroid glands, and prior Full-Scale Surveys (second-, third-, and fourth-round surveys) to continuously assess the status of thyroid glands.

1.2 Eligible persons

All Fukushima residents approximately 18 years old or younger at the time of earthquake (those born between April 2, 1992 and April 1, 2012).

1.3 Implementation Period

FY2020 and FY2022, starting in April 2020:

1.3-1 For those 18 years old or younger

The examination will be carried out over 3 years, from FY2020 through FY2022.

1.3-2 For those 19 years old or older

The examination will be carried out on an age-group basis (i.e., school grade).

FY2020: those born between FY1998 and FY2000 FY2021: those born between FY1999 and FY2001

FY2022: no eligible persons

1.3-3 For those 25 years old or older

Those who are older than 20 are recommended to receive the examination every 5 years at the ages of 25, 30, and so on. (Age 25+ Survey)

FY2020: those born in FY1995 FY2021: those born in FY1996

FY2022: those born in FY1992 and FY1997

Results of the survey for those 25 years old will be reported separately.

1.4 Implementing Organizations (number of medical facilities with agreements for implementation of thyroid examinations as of June 30, 2023)

Fukushima Prefecture commissioned Fukushima Medical University (FMU) to conduct the survey in cooperation with organizations inside and outside Fukushima for the convenience of participants.

1.4-1 Primary examination facilities

In Fukushima Prefecture 85 medical facilities
Outside Fukushima Prefecture 138 medical facilities

1.4-2 Confirmatory examination facilities

In Fukushima Prefecture 6 medical facilities, including FMU

Outside Fukushima Prefecture 39 medical facilities

1.5 Methods

1.5-1 Primary examination

Ultrasonography of the thyroid gland.

Assessments are made by specialists on the basis of the following criteria:

- Grade A
 - A1: No nodules/cysts
 - A2: Nodules ≤ 5.0 mm or cysts ≤ 20.0 mm
- Grade B
 - B: Nodules ≥ 5.1 mm or cysts ≥ 20.1 mm
 - Some A2 results may be re-classified as B results when clinically indicated.
- -Grade C
 - C: Urgent need for confirmatory examination, judging from the condition of the thyroid gland.

1.5-2 Confirmatory examination

Ultrasonography of the thyroid gland, blood and urine tests, and fine needle aspiration cytology (FNAC) if needed for those with B or C test results.

Priority is given to those in urgent clinical need. A medical follow-up may be recommended based on confirmatory exam results.

1.5-3 Flow chart




Figure 1 Flow chart

1.6 Municipalities Surveyed

The municipalities where examinations (for those 18 years old or younger) were carried out in FY2020 and FY2021 are as follows:




Figure 2 Municipalities covered for primary examinations at elementary and junior high schools




Figure 3 Municipalities covered for primary examinations at high schools and other facilities

Results of these surveys were aggregated based on the year when examinations were originally scheduled, which may differ from the year in which some examinations were actually conducted.

2. Results as of June 30, 2023

2.1 Results of the Primary Examination

2.1-1 Implementation status

The primary examination was completed for 113,937 participants (45.0%) by June 30, 2023. (Refer to Appendices 1 and 2 for the participation and progress summaries by municipalities and locations outside Fukushima.)

Results of 113,932 participants (100.0%) have been finalized and individual reports have been sent to them. (See Appendix 3 for details.)

Of these, 32,835 (28.8%) had Grade A1 results, 79,751 (70.0%) had Grade A2, 1,346 (1.2%) had Grade B, and none had Grade C.

Table 1 Progress and results of the primary examination

	Eligible	Particip	ants (per	sons)				Participa	nts with fir	nalized re	esults (%)			
	persons	1	Participation					,	4		Those ref	erred to	confirmat	ory exam
			rate (%)	Fukushima			A1		A2		В		(;
	а	b	(b/a)		С	(c/b)	d	(d/c)	е	(e/c)	f	(f/c)	g	(g/c)
FY2020	144,902	69,167	(47.7)	5,493	69,166	(100.0)	19,991	(28.9)	48,427	(70.0)	748	(1.1)	0	(0.0)
FY2021	108,036	44,770	(41.4)	2,467	44,766	(100.0)	12,844	(28.7)	31,324	(70.0)	598	(1.3)	0	(0.0)
Total	252,938	113,937	(45.0)	7,960	113,932	(100.0)	32,835	(28.8)	79,751	(70.0)	1,346	(1.2)	0	(0.0)

Table 2 Number and proportion of participants with nodules/cysts (See Appendix 4 for details.)

	Da uti ai ma utaith	Participants with nodules/cysts (%)								
	Participants with finalized results	No	dules	C	ysts					
	illialized results	≥ 5.1mm	≤ 5.0mm	≤ 5.0mm ≥20.1mm						
	а	b (b/a)	c (c/a)	d (d/a)	e (e/a)					
FY2020	69,166	748 (1.1)	379 (0.5)	1 (0.0)	48,844 (70.6)					
FY2021	44,766	598 (1.3)	284 (0.6)	0 (0.0)	31,667 (70.7)					
Total	113,932	1,346 (1.2)	663 (0.6)	1 (0.0)	80,511 (70.7)					

- Proportions are rounded to a lower decimal place. This applies to other tables as well.
- Those who receive the examination at 5-year intervals (born between FY1992 and FY1997) are excluded. The results of examinations at 5-year intervals will be shown separately.
- Examinations for those born in FY1995 (approx. 21,000) took place in FY2020, for those born in FY1996 (approx. 21,000) were in FY2021, and for those born in FY1992 (approx. 23,000) and FY1997 (approx. 20,000) were carried out in FY2022.

2.1-2 Participation rate by age group

Table 3 shows the participation rate for each age group as of April 1 of each year.

Table 3 Participation rates by age group

			Total		Age group	
	Age group*			8-11	12-17	18-24
FY2020	Eligible persons	(a)	144,902	37,105	61,911	45,886
F 1 2020	Participants	(b)	69,167	27,925	36,161	5,081
	Participation rate (%)	(b/a)	47.7	75.3	58.4	11.1
	Age group*			9-11	12-17	18-24
FY2021	Eligible persons	(a)	108,036	19,771	45,061	43,204
F12021	Participants	(b)	44,770	14,152	25,689	4,929
	Participation rate (%)	(b/a)	41.4	71.6	57.0	11.4
	Eligible persons	(a)	252,938	56,876	106,972	89,090
Total	Participants	(b)	113,937	42,077	61,850	10,010
	Participation rate (%)	(b/a)	45.0	74.0	57.8	11.2

^{*} Age groups are based on ages as of April 1 of each fiscal year.

2.1-3 Comparison of the fourth- and fifth-round survey results

Table 4 shows the comparison of results of two Full-Scale Surveys (fourth- and fifth-round surveys).

Among 106,583 (sum of *1) participants with Grade A1 or A2 results in the fourth-round survey, 105,816 (sum of *2) (99.3%) had Grade A1 or A2 results, and 767 (sum of *3) (0.7%) had Grade B results in the fifth-round survey.

Among 546 participants with Grade B results in the fourth-round survey, 104 (sum of *4) (19.0%) had Grade A1 or A2 results, and 442 (81.0%) had Grade B results in the fifth-round survey.

Table 4 Comparison of the fourth- and fifth-round surveys

			Results of the	F	Results of the fift	h-round survey*	*
			fourth-round	Α	١	В	С
			survey*	A1	A2	Ь	C
			а	b	С	d	е
			(%)	(b/a)	(c/a)	(d/a)	(e/a)
		A1	34,596 *1	23,879 *2	10,582 *2	135 *3	0
	Α	Ai	(100.0)	(69.0)	(30.6)	(0.4)	(0.0)
		A2	71,987 *1	6,642 *2	64,713 *2	632 *3	0
Results of		AZ	(100.0)	(9.2)	(89.9)	(0.9)	(0.0)
the fourth-	В		546	11 *4	93 *4	442	0
round survey		Ь	(100.0)	(2.0)	(17.0)	(81.0)	(0.0)
Tourid Survey		С	0	0	0	0	0
		C	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
	Did no	ot participate	6,803	2,303	4,363	137	0
	Did fic	л ранныране	(100.0)	(33.9)	(64.1)	(2.0)	(0.0)
	Total		113,932	32,835	79,751	1,346	0
rotai		(100.0)	(28.8)	(70.0)	(1.2)	(0.0)	

^{*} Results of the fourth-round survey are from fifth-round survey participants with finalized results, not the breakdown of all fourth-round survey participants.

^{**} Results of the fifth-round survey participants who were diagnosed for each grade in the fourth-round survey.

2.2 Results of the Confirmatory Examination

2.2-1 Implementation status

By June 30, 2023, of 1,346 eligible persons, 985 (73.2%) had participated in the confirmatory examination, and 918 (93.2%) of them had completed the entire procedure of the examination. (See Appendix 5 for the implementation status of the confirmatory examinations by area.)

Of the 918 participants, 79 (A1: 5, A2: 74) (8.6%) were confirmed to meet A1 or A2 diagnostic criteria by primary examination standards (including those with other thyroid conditions) after detailed examination; 839 (91.4%) were confirmed to be outside of A1/A2 criteria.

Table 5 Progress and results of the confirmatory examination

	Those referred			Those with finalized results (%)									
	to confirmatory	Participa	ants (%)	Total		,	۱1	A2		Not A1		or A2	
	exams					A1						FN	IAC
	а	b	(b/a)	С	(c/b)	d	(d/c)	е	(e/c)	f	(f/c)	g	(g/f)
FY2020	748	611	(81.7)	583	(95.4)	4	1 (0.7)	61	(10.5)	518	(88.9)	61	(11.8)
FY2021	598	374	(62.5)	335	(89.6)		1 (0.3)	13	(3.9)	321	(95.8)	19	(5.9)
Total	1,346	985	(73.2)	918	(93.2)	į	5 (0.5)	74	(8.1)	839	(91.4)	80	(9.5)

2.2-2 Results of fine needle aspiration cytology (FNAC)

Among those who underwent FNAC, 39 people had nodules classified as malignant or suspicious for malignancy: 10 were male and 29 were female.

Participants' ages at the time of the confirmatory examination ranged from 12 to 24 (mean age: 17.7 \pm 3.0 years). The tumor diameters were from 7.0 mm to 46.7mm, and mean tumor diameter was 12.8 \pm 7.3 mm.

Of these 39 participants, 27 had Grade A (A1:9, A2:18), 6 had Grade B, consistent with results in the previous survey, and remaining 6 participants did not receive the fourth-round survey. The details of 18 participants of A2 Grade: 17 met cyst criteria, and 1 met both cyst and nodule criteria.

Table 6 Results of FNAC.

A. Municipality surveyed in FY2020

Malignant or suspicious for malignancy: 28*
Male to female ratio: 6:22

• Mean age±SD (min – max) 17.5±3.4 (12–24)

 6.6 ± 3.5 (1–12) at the time of the earthquake

• Mean tumor size±SD (min – max) 11.6±4.9 mm (7.0–30.1 mm)

B. Municipalities surveyed in FY2021

Malignant or suspicious for malignancy: 11*
Male to female ratio: 4:7

• Mean age±SD (min – max) 18.2±1.6 (16–21)

7.0±2.2 (4-10) at the time of the earthquake

• Mean tumor size±SD (min – max) 16.1±10.9 mm (8.4–46.7 mm)

C. Total

Malignant or suspicious for malignancy: 39*
Male to female ratio: 10:29


• Mean age±SD (min – max) 17.7±3.0 (12–24)

6.7±3.1 (1–12) at the time of the earthquake

• Mean tumor size±SD (min – max) 12.8±7.3 mm (7.0–46.7 mm)

^{*} Appendix 6 shows surgical cases.

2.2-3 Age distribution of malignant or suspected malignant cases diagnosed by FNAC Age distribution of 39 people with malignant or suspected malignant nodules based on their age as of March 11, 2011 is per Figure 4, and age distribution based on their age at the time of confirmatory examination is per Figure 5.



Note: Those aged between 13 and 18 at the time of disaster are not included in the fifth-round survey participants. The horizontal axis begins at -1 to include those born between April 2, 2011 and April 1, 2012.

*Those born between March 12 and April 1, 2011 are included in age 0.

Figure 4 Age as of March 11, 2011




Figure 5 Age as of the date of confirmatory examination

2.2-4 Basic Survey results for those with malignant or suspicious nodules by FNAC Of the 39 people with malignant or suspicious nodules, 25 (64.1%) had participated in the Basic Survey (for external radiation dose estimation), and all 25 received their results. The highest effective dose documented was 2.4 mSv.

Table 7 A breakdown of dose estimates for Basic Survey participants

Effective desc	Age at the time of the disaster										
Effective dose (mSv)	0-	0–5		10	11–15 16–18		To	Total			
(IIIOV)	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	
<1	1	4	2	6	0	3	0	0	3	13	
<2	1	1	1	1	1	1	0	0	3	3	
<5	0	2	0	0	1	0	0	0	1	2	
<10	0	0	0	0	0	0	0	0	0	0	
<20	0	0	0	0	0	0	0	0	0	0	
≥ 20	0	0	0	0	0	0	0	0	0	0	
Total	2	7	3	7	2	4	0	0	7	18	




Figure 6 Effective doses of Basic Survey participants

2.2-5 Blood and urinary iodine test results

Table 8 Blood test results

	FT4 ¹ (ng/dl		FT3 ²⁾ (pg/mL)		TSH (µIU/r		Tg ⁴⁾ (ng/mL)	TgAb ⁵⁾ (IU/mL)	TPOAb ⁶⁾ (IU/mL)
Reference Range	0.95–1.	74 ⁷⁾	2.13–4.07 ⁷⁾		0.340-3	.880 ⁷⁾	≤ 33.7	< 28.0	< 16.0
Malignant or suspicious : 39	1.2±0.2	(5.1%)	3.4±0.4	(2.6%)	1.3±0.7	(10.3%)	73.4±338.5 (15.4%)	17.9%	15.4%
Other: 803	1.2±0.2	(5.1%)	3.6±0.8	(7.3%)	1.3±1.2	(8.8%)	31.4±85.8 (15.6%)	8.7%	7.3%

Table 9 Urinary iodine test results

µg/day

	Minimum	25th percentile	Median	75th percentile	Maximum
Malignant or suspicious : 37	36	126	175	396	1311
Other: 802	21	114	193	334	12670

- 1) FT4: free thyroxine; thyroid hormone binding 4 iodines; higher among patients with thyrotoxicosis (such as Graves' disease) and lower with hypothyroidism (such as Hashimoto's thyroiditis).
- 2) FT3: free triiodothyronine; thyroid hormone binding 3 iodines; higher among patients with thyrotoxicosis (such as Graves' disease) and lower with hypothyroidism (such as Hashimoto's thyroiditis).
- TSH: thyroid-stimulating hormone; higher among patients with Hashimoto's disease and lower with Graves'
 disease
- 4) Tg: thyroglobulin; higher when thyroid tissue is destroyed or when neoplastic tissue produces thyroglobulin.
- 5) TgAb: anti-thyroglobulin antibody; higher among patients with Hashimoto's disease and Graves' disease.
- 6) TPOAb: anti-thyroid peroxidase antibody; higher among patients with Hashimoto's disease or Graves' disease.
- 7) Reference intervals vary according to age.

2.2-6 Confirmatory examination results by area

The percentages of those with malignant or suspicious nodules were 0.04% in the 13 municipalities of the nationally-designated evacuation zone and Nakadori, 0.03% in Hamadori, and 0.02 in Aizu.

Table 10 Confirmatory examination results by area

	The fifth- round survey participants (persons)		efered to xam (persons) te (%)	Those who participated confirmatory exam (persons)	Malignant or suspicious (persons) and rate(%)	
	а	b b/a		а	С	c/a
13 municipalities ¹⁾	14,784	156	1.1	121	6	0.04
Nakadori ²⁾	65,582	739	1.1	594	24	0.04
Hamadori ³⁾	20,782	293	1.4	168	6	0.03
Aizu ⁴⁾	12,789	158	1.2	102	3	0.02
Total	113,937	1,346	1.2	985	39	0.03

¹⁾ Tamura City, Minamisoma City, Date City, Kawamata Town, Hirono Town, Naraha Town, Tomioka Town, Kawauchi Village, Okuma Town, Futaba Town, Namie Town, Katsurao Village, Iitate Village

²⁾ Fukushima City, Koriyama City, Shirakawa City, Sukagawa City, Nihonmatsu City, Motomiya City, Koori Town, Kunimi Town, Otama Village, Kagamiishi Town, Tenei Village, Nishigo Village, Izumizaki Village, Nakajima Village, Yabuki Town, Tanagura Town, Yamatsuri Town, Hanawa Town, Samegawa Village, Ishikawa Town, Tamakawa Village, Hirata Village, Asakawa Town, Furudono Town, Miharu Town, Ono Town

³⁾ Iwaki City, Soma City, Shinchi Town

⁴⁾ Aizuwakamatsu City, Kitakata City, Shimogo Town, Hinoemata Village, Tadami Town, Minamiaizu Town, Kitashiobara Village, Nishiaizu Town, Bandai Twon, Inawashiro Town, Aizubange Town, Yugawa Village, Yanaizu Town, Mishima Town, Kaneyama Town, Showa Village, Aizumisato Town

3. Mental Health Care

We provide the following support for thyroid examination participants.

3.1 Support for Primary Examination Participants

After the examination, medical doctors offer person-to-person explanation on examination results, showing ultrasound images in private consultation booths at examination venues set up in public facilities.

Consultation booths were set up at all venues for examinations conducted in and after April 2020; as of June 30, 2023, all 2,753 participants (100%) have visited these consultation booths.

3.2 On-location Lectures and Information Sessions

To help participants and their parents/guardians improve their understanding of the thyroid examination, we have conducted on-location lectures and information sessions.

By March 31, 2023, a total of 607 people participated in these sessions offered at 11 locations: 3 elementary schools, 4 junior high schools and 4 high schools.

3.3 Support for Confirmatory Examination Participants

A support team has been set up within Fukushima Medical University to offer psychological support to address the anxiety and concerns of confirmatory examination participants during examination. The team also answers questions and offers counseling via our website.

Since the start of the fifth-round survey, 393 participants (126 males and 267 females) have received support as of June 30, 2023. The number of support sessions provided was 694 in total. Of these, 390 (56.2%) received support at the participants' first examination and 304 (43.8%) at subsequent examinations.

For those who proceeded to regular insured medical care, the support team continues to provide support in cooperation with teams of medical staff at hospitals.

Appendix 1 Implementation status of the TUE primary examination, by municipality

As of June 30, 2023

	Number of eligible persons	Participants	Participation outside	Participation rate(%)		icipants and par by age group ²⁾	ticipation rate	Participants living outside Fukushima	%
	а	b	Fukushima ¹⁾	b/a	8–11	12–17	18–24	c ³⁾	c/b
Municipalities surveye	ed in FY2020					•			
Kawamata	1,567	739	14	47.2	238	431	70	35	4.7
Nawamata	1,567	739	14	47.2	32.2	58.3	9.5	35	4.7
Namie	2,478	953	235	38.5	210	547	196	234	24.6
Ivaillie	2,476	900	233	36.3	22.0	57.4	20.6	234	24.0
litate	731	345	20	47.2	88	202	55	25	7.2
mato	701	0.10	20	77.2	25.5	58.6	15.9	20	7.2
Minamisoma	8,849	3,974	570	44.9	1,201	2,253	520	611	15.4
	-,-	-,-			30.2	56.7	13.1		
Date	7,412	4,039	166	54.5	1,143	2,284	612	156	3.9
	,				28.3	56.5	15.2		
Tamura	4,577	2,281	52	49.8	803	1,227	251	75	3.3
					35.2	53.8	11.0		
Hirono	647	289	28	44.7	68 23.5	166	55 19.0	25	8.7
					73	57.4 221	75		
Naraha	916	369	44	40.3	19.8		******************	43	11.7
					153	59.9 412	20.3 150	 	
Tomioka	1,980	715	122	36.1	21.4	57.6	21.0	127	17.8
					20	59	19		
Kawauchi	225	98	7	43.6	20.4	60.2	19.4	8	8.2
					145	392	133		
Okuma	1,771	670	117	37.8	21.6	58.5	19.9	116	17.3
					51	155	41		
Futaba	839	247	48	29.4	20.6	62.8	16.6	50	20.2
					14	39	12		
Katsurao	148	65	3	43.9	21.5	60.0	18.5	5	7.7
- · · ·	07.000	40.500	4 440	40.0	4,862	11,047	2,690	4.057	7.0
Fukushima	37,320	18,599	1,412	49.8	26.1	59.4	14.5	1,357	7.3
NEL	0.000	0.740	100	50.7	1,126	2,156	431	440	0.0
Nihonmatsu	6,920	3,713	160	53.7	30.3	58.1	11.6	143	3.9
Motomiya	4,232	2,211	78	52.2	663	1,302	246	73	3.3
IVIOIOIIIIya	4,232	2,211	76	52.2	30.0	58.9	11.1	73	3.3
Otama	1,122	681	18	60.7	214	384	83	14	2.1
Otania	1,122		10		31.4	56.4	12.2		2
Koriyama	45,739	20,618	1,964	45.1	4,729	12,879	3,010	1,899	9.2
,	13,122		.,		22.9	62.5	14.6	1,000	
Koori	1,375	789	25	57.4	224	467	98	28	3.5
	·				28.4	59.2	12.4		
Kunimi	1,022	559	20	54.7	126	349	84 15.0	22	3.9
	+				22.5 95	62.4 180	15.0 57	 	
Tenei	728	332	19	45.6	28.6	54.2	17.2	11	3.3
	+				1,229	2,366	645		
Shirakawa	8,566	4,240	257	49.5	29.0	55.8	15.2	243	5.7
					399	740	205		
Nishigo	2,856	1,344	77	47.1	29.7	55.1	15.3	64	4.8
					105	245	44		
Izumizaki	893	394	7	44.1	26.6	62.2	11.2	9	2.3
1.51					218	525	160		
Miharu	1,989	903	30	45.4	24.1	58.1	17.7	30	3.3
Cultitud	444.000	00.467	E 400	477	18,197	41,028	9,942	F 400	7.0
Subtotal	144,902	69,167	5,493	47.7	26.3	59.3	14.4	5,403	7.8

^{*1)} The number of participants who received the examination at facilities outside Fukushima (as of May 31, 2023).

^{*2)} Split cells show the number of participants above the corresponding percentage.

^{*3)} The number of participants who have resident registration outside of Fukushima.

[·]Age groups are based on participants' age at the Full-Scale Survey (fifth-round survey). This applies to other tables hereafter.

	Number of eligible persons	Participants	Participation outside	Participation rate(%)		ticipants and par by age group ²⁾	ticipation rate	Participants living outside Fukushima	%
	а	b	Fukushima ¹⁾	b/a	8–11	12–17	18–24	c ³⁾	c/b
Municipalities surveye					2,130	12,306	4,141		
lwaki	42,530	18,577	1,368	43.7	11.5	66.2	22.3	1,224	6.6
Sukagawa	10,705	4,582	181	42.8	773 16.9	3,055 66.7	754 16.5	173	3.8
Soma	4,771	1,781	167	37.3	325 18.2	1,204 67.6	252 14.1	188	10.6
Kagamiishi	1,835	818	28	44.6	142	552	124	20	2.4
					17.4 61	67.5 279	15.2 84		
Shinchi	983	424	29	43.1	14.4 54	65.8	19.8	29	6.8
Nakajima	706	266	9	37.7	20.3	169 63.5	43 16.2	6	2.3
Yabuki	2,326	977	22	42.0	217 22.2	639 65.4	121 12.4	20	2.0
Ishikawa	1,860	790	25	42.5	161	489	140	21	2.7
V	005	200	40	44.7	20.4 66	61.9 207	17.7 33	7	0.0
Yamatsuri	685	306	13	44.7	21.6 73	67.6 268	10.8 67	/	2.3
Asakawa	913	408	21	44.7	17.9	65.7	16.4	14	3.4
Hirata	838	371	9	44.3	86 23.2	220 59.3	65 17.5	7	1.9
Tanagura	2,049	847	32	41.3	178	562	107	32	3.8
					21.0 83	66.4 262	12.6 73		
Hanawa	1,070	418	8	39.1	19.9	62.7	17.5	12	2.9
Samegawa	457	191	4	41.8	43 22.5	129 67.5	19 9.9	3	1.6
Ono	1,252	502	7	40.1	107 21.3	339 67.5	56 11.2	5	1.0
Tamakawa	920	386	9	42.0	68	258	60	5	1.3
					17.6 71	66.8 199	15.5 67		
Furudono	692	337	17	48.7	21.1	59.1	19.9	9	2.7
Hinoemata	75	16	2	21.3	3 18.8	11 68.8	12.5	0	0.0
Minamiaizu	1,788	666	20	37.2	148 22.2	445 66.8	73 11.0	18	2.7
Kaneyama	114	38	0	33.3	6	25	7	0	0.0
					15.8 9	65.8 22	18.4		
Showa	101	33	5	32.7	27.3	66.7	6.1	5	15.2
Mishima	131	45	0	34.4	12 26.7	24 53.3	20.0	1	2.2
Shimogo	646	216	3	33.4	41 19.0	143 66.2	32 14.8	2	0.9
Kitakata	5,939	2,227	66	37.5	393	1,515	319	62	2.8
					17.6 43	68.0 133	14.3 25		
Nishiaizu	618	201	5	32.5	21.4	66.2	12.4	4	2.0
Tadami	475	212	5	44.6	38 17.9	150 70.8	11.3	7	3.3
Inawashiro	1,760	696	23	39.5	137 19.7	454 65.2	105 15.1	20	2.9
Bandai	415	159	9	38.3	32	106	21	8	5.0
					20.1 32	66.7 111	13.2		
Kitashiobara	385	163	6	42.3	19.6	68.1	12.3	6	3.7
Aizumisato	2,371	987	25	41.6	179 18.1	633 64.1	175 17.7	25	2.5
Aizubange	2,012	789	27	39.2	140 17.7	504 63.9	145 18.4	26	3.3
Yanaizu	393	148	3	37.7	31	98	19	2	1.4
					20.9 950	66.2 4,003	12.8 1,029		
Aizuwakamatsu	15,770	5,982	315	37.9	15.9 38	66.9	17.2	297	5.0
Yugawa	451	211	4	46.8	18.0	130 61.6	20.4	5	2.4
Subtotal	108,036	44,770	2,467	41.4	6,870 15.3	29,644 66.2	8,256 18.4	2,263	5.1
Total	252,938	113,937	7,960	45.0	25,067 22.0	70,672 62.0	18,198 16.0	7,666	6.7

Appendix 2 Implementation status of the TUE primary examination, by prefecture

As of May 31, 2023

Prefecture	Number of medical facilities	Participants (persons)	Prefecture	Number of medical facilities	Participants (persons)	Prefecture	Number of medical facilities	Participants (persons)
Hokkaido	6	195	Fukui	1	12	Hiroshima	2	17
Aomori	2	94	Yamanashi	2	65	Yamaguchi	1	14
lwate	3	182	Nagano	4	104	Tokushima	1	4
Miyagi	2	1,753	Gifu	2	13	Kagawa	1	13
Akita	1	131	Shizuoka	3	75	Ehime	3	13
Yamagata	3	354	Aichi	5	144	Kochi	1	8
Ibaraki	4	476	Mie	1	17	Fukuoka	3	56
Tochigi	8	542	shiga	1	15	Saga	1	6
Gunma	2	154	Kyoto	3	49	Nagasaki	3	20
Saitama	4	443	Osaka	10	109	Kumamoto	1	19
Chiba	5	353	Hyogo	2	99	Oita	1	12
Tokyo	22	1,362	Nara	2	16	Miyazaki	1	12
Kanagawa	7	537	Wakayama	1	4	Kagoshima	1	6
Niigata	3	346	Tottori	1	2	Okinawa	1	22
Toyama	2	21	Shimane	1	11			
Ishikawa	1	25	Okayama	3	35	Total	138	7,960

The number of participants examined at medical facilities outside Fukushima.

Appendix 3 TUE primary examination results, by municipality

As of June 30, 2023

	Number of participants (persons)	Those with finalized results (persons)		(persons	cipants by gra s and %)	ide	Number of par nodules (per	•	Number of pa	
		b	Δ1		В	С	>F 1	< F. One no	>20 1	< 20.0
Municipalities surveyed	a d in EV2020	b/a (%)	A1	A2			≥5.1mm	≤5.0mm	≥20.1mm	≤20.0m
ividi il cipalities sui veyet	1111112020	739	227	506	6	0	6	5	0	508
Kawamata	739	100.0	30.7	68.5	0.8	0.0	0.8	0.7	0.0	68.7
		953	297	640	16	0.0	16	5	0	649
Namie	953	100.0	31.2	67.2	1.7	0.0	1.7	0.5	0.0	68.1
litate	345	345	104	231	10	0	10	0	0	240
litate	040	100.0	30.1	67.0	2.9	0.0	2.9	0.0	0.0	69.6
Minamisoma	3,974	3,974	1,234	2,697	43	0	43	14	0	2,720
	-,	100.0	31.1	67.9	1.1	0.0	1.1	0.4	0.0	68.4
Date	4,039	4,039	1,159	2,847	33	0	33	23	0	2,859
		100.0	28.7	70.5	0.8	0.0	0.8	0.6	0.0	70.8
Tamura	2,281	2,281	718	1,540	23	0	23	10	0	1,548
		100.0 289	31.5 93	67.5 191	1.0 5	0.0	1.0 5	0.4	0.0	67.9 192
Hirono	289	100.0	32.2	66.1	1.7	0.0	1.7	0.3	0.0	192 66.4
		369	114	253	2	0.0	2	1	0.0	253
Naraha	369	100.0	30.9	68.6	0.5	0.0	0.5	0.3	0.0	68.6
		714	211	497	6	0.0	6	4	0.0	501
Tomioka	715	99.9	29.6	69.6	0.8	0.0	0.8	0.6	0.0	70.2
.,		98	32	65	1	0	1	0	0	66
Kawauchi	98	100.0	32.7	66.3	1.0	0.0	1.0	0.0	0.0	67.3
Okuma	670	670	196	464	10	0	10	9	0	464
Okuma	670	100.0	29.3	69.3	1.5	0.0	1.5	1.3	0.0	69.3
Futaba	247	247	72	174	1	0	1	0	0	175
radada	2	100.0	29.1	70.4	0.4	0.0	0.4	0.0	0.0	70.9
Katsurao	65	65	29	36	0	0	0	0	0	36
		100.0	44.6	55.4	0.0	0.0	0.0	0.0	0.0	55.4
Fukushima	18,599	18,599	5,409	13,005	185	0	185	97	0	13,102
		100.0 3,713	29.1 1,158	69.9 2,504	1.0 51	0.0	1.0 51	0.5 27	0.0	70.4 2,535
Nihonmatsu	3,713	100.0	31.2	67.4	1.4	0.0	1.4	0.7	0.0	68.3
		2,211	668	1,522	21	0.0	21	9	0.0	1,533
Motomiya	2,211	100.0	30.2	68.8	0.9	0.0	0.9	0.4	0.0	69.3
_		681	198	472	11	0.0	11	3	0.0	479
Otama	681	100.0	29.1	69.3	1.6	0.0	1.6	0.4	0.0	70.3
IZ a situa una a	00.040	20,618	5,588	14,804	226	0	226	128	0	14,944
Koriyama	20,618	100.0	27.1	71.8	1.1	0.0	1.1	0.6	0.0	72.5
Koori	789	789	245	535	9	0	9	2	0	542
ROOH	709	100.0	31.1	67.8	1.1	0.0	1.1	0.3	0.0	68.7
Kunimi	559	559	181	371	7	0	7	2	0	377
		100.0	32.4	66.4	1.3	0.0	1.3	0.4	0.0	67.4
Tenei	332	332	88	239	5	0	5	0	1	242
		100.0	26.5	72.0	1.5	0.0	1.5	0.0	0.3	72.9
Shirakawa	4,240	4,240	1,201	2,993	46	0	46	25	0	3,019
		100.0 1,344	28.3 402	70.6 924	1.1 18	0.0	1.1	0.6	0.0	71.2
Nishigo	1,344	1,344	29.9	68.8	1.3	0.0	18 1.3	0.4	0.0	936 69.6
		394	119	271	4	0.0	4	2	0.0	272
Izumizaki	394	100.0	30.2	68.8	1.0	0.0	1.0	0.5	0.0	69.0
		903	248	646	9	0.0	9	6	0.0	652
Miharu	903	100.0	27.5	71.5	1.0	0.0	1.0	0.7	0.0	72.2
0.11.11	20.45-	69,166	19,991	48,427	748	0	748	379	1	48,844
Subtotal	69,167	100.0	28.9	70.0	1.1	0.0	1.1	0.5	0.0	70.6


	Number of participants (persons)	Those with finalized results (persons)		mber of partic		ade	Number of pa nodules (per		Number of par cysts (perso	
	а	b b/a (%)	A1	A2	В	С	≥5.1mm	≤5.0mm	≥20.1mm	≤20.0m
Municipalities surveyed	l in FY2021	10.574	5 000	10.044	055	•	055	407		40.440
lwaki	18,577	18,574 100.0	5,308 28.6	13,011 70.0	255 1.4	0.0	255 1.4	107 0.6	0.0	13,148 70.8
0.1	4.500	4,582	1,255	3,255	72	0.0	72	41	0.0	3,301
Sukagawa	4,582	100.0	27.4	71.0	1.6	0.0	1.6	0.9	0.0	72.0
Soma	1,781	1,781	523	1,227	31	0	31	12	0	1,245
		100.0 818	29.4 214	68.9 593	1.7 11	0.0	1.7	0.7	0.0	69.9 595
Kagamiishi	818	100.0	26.2	72.5	1.3	0.0	1.3	0.7	0.0	72.7
Shinchi	424	424 100.0	127 30.0	290 68.4	7 1.7	0.0	7 1.7	5 1.2	0.0	293 69.1
Nakajima	266	266	78	187	1.7	0.0	1.7	2	0.0	188
Haitajina		100.0 977	29.3 279	70.3 693	0.4 5	0.0	0.4	0.8	0.0	70.7 696
Yabuki	977	100.0	28.6	70.9	0.5	0.0	0.5	0.4	0.0	71.2
Ishikawa	790	790	226	557	7	0	7	5	0	561
BIIIKawa	790	100.0	28.6	70.5	0.9	0.0	0.9	0.6	0.0	71.0
Yamatsuri	306	306 100.0	70 22.9	230 75.2	2.0	0.0	2.0	1.3	0.0	235 76.8
		408	102	303	3	0.0	3	1.3	0.0	305
Asakawa	408	100.0	25.0	74.3	0.7	0.0	0.7	1.0	0.0	74.8
Hirata	371	371	119	247	5	0	5	1	0	251
		100.0	32.1	66.6	1.3	0.0	1.3	0.3	0.0	67.7
Tanagura	847	847 100.0	224 26.4	611 72.1	12 1.4	0.0	12 1.4	0.2	0.0	618 73.0
		418	106	302	10	0.0	10	0.2	0.0	307
Hanawa	418	100.0	25.4	72.2	2.4	0.0	2.4	0.0	0.0	73.4
Samegawa	191	191	49	141	1	0	1	1	0	142
		100.0 501	25.7 143	73.8 354	0.5	0.0	0.5	0.5	0.0	74.3 357
Ono	502	99.8	28.5	70.7	0.8	0.0	0.8	0.8	0.0	71.3
Tamagawa	386	386	125	256	5	0	5	1	0	260
Taillagawa	300	100.0	32.4	66.3	1.3	0.0	1.3	0.3	0.0	67.4
Furudono	337	337 100.0	91 27.0	241 71.5	5 1.5	0.0	5 1.5	0.9	0.0	245 72.7
		16	4	12	0	0.0	0	0.9	0.0	12.7
Hinoemata	16	100.0	25.0	75.0	0.0	0.0	0.0	0.0	0.0	75.0
Minamiaizu	666	666	205	453	8	0	8	2	0	459
		100.0 38	30.8 12	68.0 26	1.2	0.0	1.2	0.3	0.0	68.9 26
Kaneyama	38	100.0	31.6	68.4	0.0	0.0	0.0	0.0	0.0	68.4
Showa	33	33	13	20	0	0	0	0	0	20
0.10.114		100.0	39.4	60.6	0.0	0.0	0.0	0.0	0.0	60.6
Mishima	45	45 100.0	8 17.8	36 80.0	1 2.2	0.0	1 2.2	1 2.2	0.0	37 82.2
Chiman	040	216	66	146	4	0	4	1	0.0	148
Shimogo	216	100.0	30.6	67.6	1.9	0.0	1.9	0.5	0.0	68.5
Kitakata	2,227	2,227	692	1,509	26	0	26	10	0	1,525
		100.0 201	31.1 44	67.8 154	1.2	0.0	1.2	0.4	0.0	68.5 155
Nishiaizu	201	100.0	21.9	76.6	1.5	0.0	1.5	1.5	0.0	77.1
Tadami	212	212	53	158	1	0	1	3	0	158
		100.0 696	25.0 195	74.5 488	0.5	0.0	0.5 13	1.4	0.0	74.5 496
Inawashiro	696	100.0	28.0	488 70.1	13 1.9	0.0	1.9	0.9	0.0	71.3
Bandai	159	159	44	114	1	0	1	1	0.0	114
Danual	159	100.0	27.7	71.7	0.6	0.0	0.6	0.6	0.0	71.7
Kitashiobara	163	163 100.0	47 28.8	113 69.3	3 1.8	0.0	3 1.8	0.6	0.0	114 69.9
A1- 1		987	297	681	9	0.0	9	7	0.0	686
Aizumisato	987	100.0	30.1	69.0	0.9	0.0	0.9	0.7	0.0	69.5
Aizubange	789	789	203	571	15	0	15	5	0	581
_		100.0 148	25.7 51	72.4 96	1.9 1	0.0	1.9	0.6	0.0	73.6 96
Yanaizu	148	100.0	34.5	64.9	0.7	0.0	0.7	0.7	0.0	64.9
Aizuwakamatu	5,982	5,982	1,798	4,113	71	0	71	39	0	4,155
	,,	100.0 211	30.1 73	68.8 136	1.2	0.0	1.2	0.7	0.0	69.5 138
Yugawa	211	100.0	34.6	64.5	0.9	0.0	0.9	0.9	0.0	65.4
Subtotal	44,770	44,766	12,844	31,324	598	0	598	284	0	31,667
Subtotal	77,770	100.0	28.7	70.0	1.3	0.0	1.3	0.6	0.0	70.7
Total	113,937	113,932 100.0	32,835 28.8	79,751 70.0	1,346 1.2	0.0	1,346 1.2	663 0.6	1 0.0	80,511 70.7

Appendix 4 – 1 TUE primary examination results, by age and gender


As of June 30, 2023

															(Persons)
Grade Gender	A A2				г В					С			Total		
Age group	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
8-11	3,862	3,338	7,200	8,951	8,852	17,803	21	43	64	0	0	0	12,834	12,233	25,067
12-17	10,583	9,052	19,635	25,072	25,226	50,298	251	487	738	0	0	0	35,906	34,765	70,671
18-24	2,803	3,197	6,000	5,376	6,274	11,650	159	385	544	0	0	0	8,338	9,856	18,194
Total	17,248	15,587	32,835	39,399	40,352	79,751	431	915	1,346	0	0	0	57,078	56,854	113,932

Results by age group (Male)





Results by age group (Female)



As of June 30, 2023


					(persons)
Nodule size	Total		Grad	ماد	
Nodule Size	Total	Male	Female	Oracle	
None	111,923	56,410	55,513	A1	98.2%
≤ 3mm	91	27	64	A2	0.6%
≤ 5mm	572	210	362	AZ	0.076
≤ 10mm	862	284	578		
≤ 15mm	294	85	209		
≤ 20mm	114	42	72	В	1.2%
≤ 25mm	37	10	27		
≥ 25.1mm	39	10	29		
Total	113,932	57,078	56,854		






As of June 30, 2023

					(persons)
Cyst size	Total			Grad	lo
Cyst size	Total	Male	Female	Glac	16
None	33,420	17,458	15,962	A1	68.1%
≤ 3mm	44,219	23,432	20,787		00.170
≤ 5mm	31,053	14,331	16,722		
≤ 10mm	5,119	1,829	3,290	A2	31.9%
≤ 15mm	106	25	81		31.9%
≤ 20mm	14	3	11		
≤ 25mm	0	0	0	В	0.001%
≥ 25.1mm	1	0	1	В	0.001%
Total	113,932	57,078	56,854		





Appendix 5 Implementation status of the TUE confirmatory examination, by area

As of June 30, 2023

	Those who participated in	Those refered to	Those who	participated in	confirmatory e	examination	Those with finalized results (persons)				
	primary examination (persons)	confirmatory examination (persons)	Total	8-11 years old	12-17 years old	18 and older	Total	A1	A2	Other than	A1 or A2
	а	b	С	d	е	f	g	h	i	j	k
		b/a (%)	c/b (%)	d/c (%)	e/c (%)	f/c (%)	g/c (%)	h/g (%)	i/g (%)	j/g (%)	k/j (%)
13 municipalities ¹⁾	14,784	156	121	8	58	55	117	0	12	105	8
13 municipalities	14,784	1.1	77.6	6.6	47.9	45.5	96.7	0.0	10.3	89.7	7.6
Nakadori ²⁾	65,582	739	594	27	294	273	554	4	54	496	57
Nakadori 7	05,562	1.1	80.4	4.5	49.5	46.0	93.3	0.7	9.7	89.5	11.5
Hamadori ³⁾	20,782	293	168	2	57	109	150	0	6	144	8
Hamadon	20,762	1.4	57.3	1.2	33.9	64.9	89.3	0.0	4.0	96.0	5.6
Aizu ⁴⁾	12,789	158	102	4	49	49	97	1	2	94	7
AiZu ′	12,709	1.2	64.6	3.9	48.0	48.0	95.1	1.0	2.1	96.9	7.4
		1,346	985	41	458	486	918	5	74	839	80
Total	113,937	1.2	73.2	4.2	46.5	49.3	93.2	0.5	8.1	91.4	9.5

- 1) Tamura City, Minamisoma City, Date City, Kawamata Town, Hirono Town, Naraha Town, Tomioka Town, Kawauchi Village, Okuma Town, Futaba Town, Namie Town, Katsurao Village, Iitate Village
- 2) Fukushima City, Koriyama City, Shirakawa City, Sukagawa City, Nihonmatsu City, Motomiya City, Koori Town, Kunimi Town, Otama Village, Kagamiishi Town, Tenei Village, Nishigo Village, Izumizaki Village, Nakajima Village, Yabuki Town, Tanagura Town, Yamatsuri Town, Hanawa Town, Samegawa Village, Ishikawa Town, Tamakawa Village, Hirata Village, Asakawa Town, Furudono Town, Miharu Town, Ono Town
- 3) Iwaki City, Soma City, Shinchi Town
- 4) Aizuwakamatsu City, Kitakata City, Shimogo Town, Hinoemata Village, Tadami Town, Minamiaizu Town, Kitashiobara Village, Nishiaizu Town, Bandai Twon, Inawashiro Town, Aizubange Town, Yugawa Village, Yanaizu Town, Mishima Town, Kaneyama Town, Showa Village, Aizumisato Town

Appendix 6 Surgical cases for malignancy or suspicion of malignancy

1. Municipalities surveyed in FY2020

Malignant or suspicious for malignancy: 28

(Surgical cases: 21, Papillary thyroid carcinomas: 21)

2. Municipalities surveyed in FY2021

Malignant or suspicious for malignancy: 11

(Surgical cases: 6, Papillary thyroid carcinomas: 6)

3. Total

Malignant or suspicious for malignancy: 39

(Surgical cases: 27, Papillary thyroid carcinomas: 27)

Report on the TUE Full-Scale Survey (sixth-round survey)

As of June 30, 2023

1. Summary

1.1 Purpose

In order to monitor the long-term health of children, we are continuing the Full-Scale Survey (sixth-round survey), following the Preliminary Baseline Survey for background assessment of thyroid glands, and prior Full-Scale Surveys (second-, third-, fourth, and fifth-round surveys) to continuously assess the status of thyroid glands.

1.2 Eligible persons

All Fukushima residents approximately 18 years old or younger at the time of earthquake (those born between April 2, 1992 and April 1, 2012).

1.3 Implementation Period

FY2023 and FY2024, starting in April 2023:

1.3-1 For those 18 years old or younger

The examination will be carried out for 2 years: FY2023 and FY2024.

1.3-2 For those 19 years old or older

The examination will be carried out on an age-group basis (i.e., school grade).

FY2023: those born between FY2000 and FY2003

FY2024: those born in FY2004

1.3-3 For those 25 years old or older

Those who are older than 20 are recommended to receive the examination every 5 years at the ages of 25, 30, and so on.(Age 25+ Survey)

FY2023: those born in FY1993 and FY1998 FY2024: those born in FY1994 and FY1999

Results of the survey for those 25 years old will be reported separately.

1.4 Implementing Organizations (number of medical facilities with agreements for implementation of thyroid examinations as of June 30, 2023)

Fukushima Prefecture commissioned Fukushima Medical University (FMU) to conduct the survey in cooperation with organizations inside and outside Fukushima for the convenience of participants.

1.4-1 Primary examination facilities

In Fukushima Prefecture 85 medical facilities
Outside Fukushima Prefecture 138 medical facilities

1.4-2 Confirmatory examination facilities

In Fukushima Prefecture 6 medical facilities, including FMU

Outside Fukushima Prefecture 39 medical facilities

1.5 Methods

1.5-1 Primary examination

Ultrasonography of the thyroid gland.

Assessments are made by specialists on the basis of the following criteria:

- Grade A

A1: No nodules/cysts

A2: Nodules ≤ 5.0 mm or cysts ≤ 20.0 mm

- Grade B
 - B: Nodules ≥ 5.1 mm or cysts ≥ 20.1 mm
 - Some A2 results may be re-classified as B results when clinically indicated.
- -Grade C
 - C: Urgent need for confirmatory examination, judging from the condition of the thyroid gland.

1.5-2 Confirmatory examination

Ultrasonography of the thyroid gland, blood and urine tests, and fine needle aspiration cytology (FNAC) if needed for those with B or C test results.

Priority is given to those in urgent clinical need. A medical follow-up may be recommended based on confirmatory exam results.

1.5-3 Flow chart




Figure 1 Flow chart

1.6 Municipalities Surveyed

The municipalities where examinations (for those 18 years old or younger) were carried out in FY2023 and FY2024 are as follows:




Figure 2 Municipalities covered for primary examinations in FY2023 and FY2024

2. Results as of June 30, 2023

2.1 Results of the Primary Examination

2.1-1 Implementation status

The primary examination was completed for 4,956 participants (2.3%) by June 30, 2023.

Results of 208 participants (4.2%) have been finalized and individual reports have been sent to them.

Of these, 51 (24.5%) had Grade A1 results, 153 (73.6%) had Grade A2, 4 (1.9%) had Grade B, and none had Grade C.

Table 1 Progress and results of the primary examination

	Eligible	Particip	ants (pe	ersons)		Participants with finalized results (%)										
	persons	1	Participati Outside					,	4		Those	referred ex	to confi am	rmatory		
			(%)	ma			A	l	A	2		В		С		
	а	b	(b/a)		С	(c/b)	d	(d/c)	е	(e/c)	f	(f/c)	g	(g/c)		
FY2023	121,788	4,835	(4.0)	192	202	(4.2)	50	(24.8)	148	(73.3)	4	(2.0)	((0.0)		
FY2024	90,077	121	(0.1)	0	6	(5.0)	1	(16.7)	5	(83.3)	((0.0)	((0.0)		
Total	211,865	4,956	(2.3)	192	208	(4.2)	51	(24.5)	153	(73.6)	4	(1.9)	((0.0)		

Table 2 Number and proportion of participants with nodules/cysts.

	Participante	Participants with nodules/cysts (%)										
	Participants - with finalized	Nod	ules	Cysts								
	results	≥ 5.1mm	≤ 5.0mm	≥20.1mm	≤ 20.0mm							
	а	b (b/a)	c (c/a)	d (d/a)	e (e/a)							
FY2023	202	4 (2.0)	2 (1.0)	0 (0.0)	150 (74.3)							
FY2024	6	0 (0.0)	0 (0.0)	0 (0.0)	5 (83.3)							
Total	208	4 (1.9)	2 (1.0)	0 (0.0)	155 (74.5)							

- Proportions are rounded to a lower decimal place. This applies to other tables as well.
- Those who receive the examination at 5-year intervals (born between FY1992 and FY1999) are excluded. The results of examinations at 5-year intervals will be reported separately.
- Examinations for those born in FY1993 (approx. 22,000) and FY1998 (approx. 21,000) take place in FY2023. Examinations for those born in FY1994 (approx. 22,000) and FY1999 (approx. 20,000) will be carried out in FY2024.

2.1-2 Participation rate by age group

Table 3 shows the participation rate for each age group as of April 1 of each year.

Table 3 Participation rates by age group

			Total		Age group	
	Age group*			11 years old	12-17	18-24
FY2023	Eligible persons	(a)	121,788	8,404	58,629	54,755
F12023	Participants	(b)	4,835	1,058	3,767	10
	Participation rate (%)	(b/a)	4.0	12.6	6.4	0.0
	Age group *				12-17	18-24
FY2024	Eligible persons	(a)	90,077		41,637	48,440
F12024	Participants	(b)	121		112	9
	Participation rate (%)	(b/a)	0.1		0.3	0.0
	Eligible persons	(a)	211,865	8,404	100,266	103,195
Total	Participants	(b)	4,956	1,058	3,879	19
	Participation rate (%)	(b/a)	2.3	12.6	3.9	0.0

^{*} Age groups are formed with the age as of April 1 of each fiscal year

2.1-3 Comparison of the fifth- and sixth-round survey results

Table 4 shows the comparison of results of two Full-Scale Surveys (fifth- and sixth-round surveys).

Among 192 (sum of *1) participants with Grade A1 or A2 results in the fifth-round survey, 188 (sum of *2, 97.9%) had Grade A results and 4 (sum of *3, 2.1%) had Grade B results in the sixth-round survey.

Table 4 Comparison of the fifth- and sixth-round surveys

			Results of the fifth-	R	esults of the six	th-round survey*	**
			round survey*	P	١	Б	0
				A1	A2	В	С
			а	b	С	d	е
			(%)	(b/a)	(c/a)	(d/a)	(e/a)
		A1	65 *1	39 *2	24 *2	2 *3	0
	A		(100.0)	(60.0)	(36.9)	(3.1)	(0.0)
		A2	127 *1	5 *2	120 *2	2 *3	0
Results of		AZ	(100.0)	(3.9)	(94.5)	(1.6)	(0.0)
the fifth-round		В	0	0	0	0	0
survey			(100.0)	(0.0)	(0.0)	(0.0)	(0.0)
Survey		С	0	0	0	0	0
			(0.0)	(0.0)	(0.0)	(0.0)	(0.0)
	Did not participate		16	7	9	0	0
			(100.0)	(43.8)	(56.3)	(0.0)	(0.0)
-	Total		208	51	153	4	0
Total		(100.0)	(24.5)	(73.6)	(1.9)	(0.0)	

^{*} Results of the fifth-round survey are from sixth-round survey participants with finalized results, not the breakdown of all fifth-round survey participants.

^{**} Results of the sixth-round survey participants who were diagnosed for each grade in the fifth-round survey.

2. Mental Health Care

We provide the following support for thyroid examination participants.

2.1 On-location Lectures and Information Sessions

To help participants and their parents/guardians improve their understanding of the thyroid examination, we have conducted on-location lectures and information sessions.

Between April 2023 (the start of FY2023) and June 30, 2023, we delivered an on-location session at an elementary school for 32 students. In total, 15,725 people have participated since the start of these sessions.